कंपनी का अवलोकन
Solid Biosciences Inc. (SLDB) operates as a biotechnology enterprise dedicated to the development of novel therapies targeting neuromuscular and cardiac diseases within the United States market. The company's primary focus is centered on its lead product candidate, SGT-003, which is currently undergoing phase 1/2 clinical trials for the treatment of Duchenne muscular dystrophy, alongside SGT-212 aimed at treating Friedreich's ataxia. This organization functions within the Healthcare sector and the Biotechnology industry, representing a segment of the economy focused on high-risk, high-reward research and development activities. With a market capitalization of $789.10M and an employed workforce of 121 individuals, the firm maintains a mid-sized operational scale typical for early-stage clinical development entities. The available revenue figures are not disclosed in the current data, which suggests the company is in a capital-intensive growth phase where valuation is often driven by pipeline potential rather than established sales streams. The debt-to-equity ratio and cash position further indicate the financial posture required to sustain these long-term research initiatives without immediate profitability.
वित्तीय स्वास्थ्य
The company reported a net income of $-174,324,992 and an EBITDA of $-177,570,000 for the trailing twelve months, while revenue figures are not publicly disclosed in the provided dataset. The significant disparity between the reported net income loss and the EBITDA loss highlights a substantial cost structure burdened by non-operating expenses or interest costs that erode profitability before reaching the bottom line. Free cash flow stands at $-99,700,752, indicating that the company is currently burning cash to fund its operations and research, which limits immediate financial flexibility but is common for companies in the clinical trial stage. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, reflecting a financial state where the company has not yet generated sufficient revenue to cover its direct and operating costs. On the balance sheet, the company holds $187.85M in cash against $21.16M in debt, resulting in a debt-to-equity ratio of 11.76, which suggests a highly leveraged capital structure relative to equity. Despite the high leverage, the current ratio of 6.14 indicates robust short-term liquidity, providing ample coverage for current liabilities and ensuring the ability to meet operational obligations. Return on Equity is reported at -109.9% and Return on Assets at -53.2%, metrics that reveal management is currently generating negative returns on the capital invested, a typical characteristic of pre-revenue biotechnology firms.
मूल्यांकन आकलन
Valuation metrics for Solid Biosciences Inc. present a complex picture given the lack of positive earnings, with a P/E Ratio (TTM) listed as N/A and a Forward P/E of -4.76. The negative forward P/E and the absence of a trailing P/E imply that the market is pricing the stock based on future potential earnings that are not yet realized, rather than current profitability. The price-to-book ratio is 3.52, suggesting that the market values the company at a significant premium over its book value, likely due to the intangible value of its clinical pipeline and intellectual property. Alternative valuation multiples such as the price-to-sales ratio are N/A, and the EV/EBITDA stands at -3.50, further confirming that traditional earnings-based valuation models are not applicable to this asset at this stage. The stock has demonstrated significant volatility over the past year, trading between a 52-week high of $8.72 and a 52-week low of $2.41. The current trading price sits within this range, reflecting the inherent uncertainty and risk associated with speculative biotechnology stocks. A beta of 2.58 indicates that the stock's price volatility is 158% higher than the broader market, signifying extreme sensitivity to market movements and investor sentiment regarding clinical trial outcomes.
Growth & Income
The growth profile for Solid Biosciences Inc. is currently characterized by stagnation in reported metrics, as revenue growth year-over-year and earnings growth year-over-year are both N/A. The absence of positive revenue growth data means that earnings cannot be compared to revenue expansion at this time, as the company has not yet transitioned to a revenue-generating phase. Regarding income generation, the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This zero payout ratio is sustainable only because the company has no earnings to distribute, and instead, it retains all cash flow to reinvest into its drug development programs. Consequently, the overall growth and income profile for SLDB is defined entirely by its capital expenditure on research and development rather than shareholder distributions or organic earnings expansion. The company's strategy relies on converting its substantial cash reserves into successful clinical trials that could eventually generate revenue, rather than providing immediate income to investors.